Vaniam Group(TM) and Women Leaders in Oncology(R) honor 2026 Young Investigator Award recipients at ASCO. Recognizing Nia Beckley, MD, MEng, and Jordyn Silverstein, MD, MS, as rising physician-scientists shaping the future of cancer research and care * June 1, 2026 * 3:15 pm CHICAGO, June 1, 2026 - Conquer Cancer(R), the ASCO Foundation, presented the 2026 Young Investigator Awards (YIAs) funded by Vaniam Group(TM) and Women Leaders in Oncology(R)(WLO) at the 2026 ASCO Annual Meeting in Chicago, Illinois. The awards recognize early-career physician-scientists whose research is helping move oncology forward, from deeper biological understanding to more precise, personalized approaches to care. * Nia Beckley, MD, MEng, of the University of California, San Francisco, is the recipient of the Conquer Cancer-Vaniam Group LLC Young Investigator Award. Her work focuses on spatial profiling of immune evolution, offering new insight into how tumors adapt over time and how immunotherapies may be applied more effectively. * Jordyn Silverstein, MD, MS, of the Division of Hematology/Oncology at the University of California, Los Angeles, is the recipient of the Conquer Cancer-Women Leaders in Oncology Endowed Young Investigator Award. Her research explores circulating tumor cells as a noninvasive method to guide treatment selection and expand access to targeted therapies in ovarian cancer. "Dr. Beckley and Dr. Silverstein are advancing a more precise and connected future for oncology, one where we can better understand disease evolution and intervene earlier, more effectively, and more personally," said Deanna B. van Gestel, FASCO, Founder and CEO of Vaniam Group and Board Member of Conquer Cancer(R), the ASCO Foundation. "Their work reflects where cancer research is heading, at the intersection of technology, biology, and clinical insight." In conjunction with the award presentations, Women Leaders in Oncology will host its annual event on the evening of June 1 during the 2026 ASCO Annual Meeting, convening oncology leaders, researchers, physicians, and allies for an evening of panel discussion, community engagement, and fundraising in support of the WLO endowment. Conquer Cancer-Vaniam Group LLC Young Investigator Award Dr. Beckley's research focuses on how the immune system evolves within tumors over time, particularly in hepatocellular carcinoma. Using advanced spatial profiling and transcriptomic technologies, her work maps how immune cells interact within tumors and how those interactions change as cancer recurs. By identifying immune signatures associated with treatment response, this research addresses a central challenge in oncology: understanding why therapies succeed for some patients and not others. The goal is to support more precise treatment selection and improve long-term outcomes. Dr. Beckley is a medical oncology fellow whose background bridges engineering and medicine, reflecting the interdisciplinary approach increasingly needed to advance cancer care. Conquer Cancer-Women Leaders in Oncology Endowed Young Investigator Award Silverstein's research focuses on circulating tumor cells (CTCs) as a noninvasive approach to understanding tumor biology in ovarian cancer. Her work evaluates how CTCs may help identify patients eligible for antibody-drug conjugates, potentially reducing reliance on invasive biopsies and accelerating access to targeted therapies. The Women Leaders in Oncology Endowed Young Investigator Award reflects WLO's commitment to supporting emerging physician-scientists whose work has the potential to shape both the science and the future of leadership in oncology. By investing in research at a pivotal stage, the award helps create momentum for promising investigators and the patients their work is designed to serve. Dr. Silverstein's approach also reflects a broader shift in oncology toward real-time, blood-based monitoring that can enable faster, more informed treatment decisions and expand access to emerging therapies. "Receiving a Young Investigator Award was a dream I held from the very first days of fellowship, and having it become real is a dream come true - telling me that my work has scientific merit and that I belong at the table," said Dr. Silverstein. "Research is rarely easy, but my patients give me an unshakeable reason to persist, and this award reminds me that others believe in that mission too." About Women Leaders in Oncology Since 2014, Women Leaders in Oncology (WLO), a Vaniam Group company, has built a community dedicated to advancing leadership and opportunity in oncology. Founded by Deanna B. van Gestel, WLO brings together women oncology leaders alongside the colleagues, mentors, and allies committed to advancing them, across research, clinical care, and drug development, to foster connection, support career progression, and accelerate progress across the field. About Vaniam Group. Vaniam Group is the integrated oncology organization built for what's next, grounded in two decades of scientific depth, sustained engagement across the oncology community, and longitudinal insight that compounds with every program. For more than two decades, Vaniam has worked with biopharma to translate complexity into clarity, connecting data, insight, and engagement to inform decisions and shape strategy across oncology.

Vaniam Group appoints Cherie Myatt as Interim President. Feb 19, 2026, 16:30 ET As Interim President, Cherie Myatt will provide executive leadership across the organization, reinforcing Vaniam Group's long-term commitment to value creation. CHICAGO, Feb. 19, 2026 /PRNewswire/ - Vaniam Group announced today that Cherie Myatt has been appointed Interim President, effective immediately. "I'm excited to help shape the next phase of Vaniam Group's growth," said Cherie Myatt. "As the organization continues to expand, my focus is on strengthening how we bring insights, engagement, and execution together, so our work scales, our oncology intelligence platform integrates, and our impact for clients continues to deepen. I'm proud to work alongside this team as we build what's next for Vaniam Group." In this role, Cherie will provide executive leadership across the organization, guiding strategic direction, supporting operational excellence, and ensuring continuity as Vaniam Group continues to advance its growth and long-term vision. Cherie will work closely with the leadership team to strengthen organizational alignment and momentum during this period. In addition to serving as Interim President, Cherie leads Vaniam Group's Patient Engagement and Rare Disease capabilities, where she provides strategic leadership and helps shape the firm's long-term approach to patient-centric innovation across the life sciences ecosystem. Cherie brings deep experience as a founder, chief executive, and enterprise operator. She is the founder, former CEO, and owner of CM Group, which was acquired by OPEN Health. Following the acquisition, Cherie went on to lead and scale patient engagement capabilities within a global organization, combining an entrepreneurial mindset with experience operating at enterprise scale. She is widely respected for building high-performing teams, navigating complex organizational transitions, and translating strategy into durable impact. "Cherie is a proven leader with a rare combination of founder insight and enterprise operating experience," said Deanna van Gestel, CEO, Vaniam Group. "Her appointment as Interim President reflects the confidence we have in her judgment, leadership, and ability to guide our organization with clarity and stability." This interim appointment reflects Vaniam Group's commitment to thoughtful leadership, continuity, and long-term value creation. About Vaniam Group Vaniam Group is an oncology-led partner to biopharma companies working at the forefront of complex, high-science medicine. With deep expertise in oncology and hematology, Vaniam Group helps clients make sense of evolving data, emerging insights, and real-world dynamics so teams can make confident decisions and move programs forward with clarity. The company combines scientific depth, close collaboration with the medical community, and an integrated approach to insight and data that supports strategy across the oncology lifecycle. While oncology is where Vaniam Group's work is most established and refined, the same rigor and expertise are applied in other therapeutic areas where the science is complex and the stakes are high. SOURCE Vaniam Group LLC